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Macroautophagy (autophagy hereafter) captures and degrades intracellular proteins and organelles in lysosomes
as a quality control mechanism and recycles their components to sustain survival in starvation. Cellular
self-cannibalization by autophagy is thought to have a context-dependent role in cancer. Autophagy inactivation
is destructive to normal tissues and can promote cancer initiation while some established cancers upregulate
autophagy that promotes their survival. We are only beginning to understand the role of autophagy in cancer
and the precise mechanisms behind tumour suppression and promotion and the molecular and physiological
contexts involved.
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Autophagy has emerged as a fundamental process in cell
biology, meaning ‘to eat oneself’. What is autophagy and
how was it discovered?
It was discovered by the Ohsumi lab in Japan as a pathway
essential for yeast to survive nitrogen starvation. They dis-
covered that yeast cells cannibalised their intercellular
proteins and organelles and degraded them in the yeast
lysosome—the vacuole. Many laboratories proceeded to
investigate the reason why autophagy was important, and
it is now clear that autophagy is essential for removing
damaged intracellular components, by taking away toxic
garbage to maintain homeostasis. But the other function is
to take that degraded garbage and recycle the building
blocks to sustain metabolism in starvation.Autophagy has in the past been described as a type of
cell death, along with apoptosis and necrosis. But as you
say, it is actually a method of survival—of prolonging cell
viability when nutrients are low. Can you explain this
apparent paradox?
The concept of autophagic cell death arose from the
fact that, in some dying cells, there were lots and lots of
autophagosomes. That led the observers to think that the
presence of autophagosomes meant that autophagy wasCorrespondence: epwhite@cinj.rutgers.edu
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and this is long ago—we have come to realise that cell
death is often associated with autophagy but is not caused
by autophagy. In fact, in most cases, it is probably the cell
inducing autophagy as an attempt to save itself, in response
to a particular stress. Progressive, unrelenting autophagy,
however, could potentially be a means to cell death.
So autophagy is clearly linked to cell survival. The most
clear example is the one in yeast that I provided. There is
also some data that if you knock out the autophagy pathway
in mouse embryogenesis, the mouse will be born but will
fail to survive neonatal starvation. We have data that if you
turn off autophagy in an adult mouse, the mouse is fine for
a while but is intolerant to starvation, and over time, it will
have deterioration of a number of key tissues like the liver,
brain and muscle [1]. So, autophagy is a critical homeostatic
mechanism as it promotes tissue health and survival, and
this is a function conserved from yeast to mammals.You mentioned how autophagy promotes tissue survival.
You have spent a lot of time researching cancer and the
role for autophagy there. Can you talk about how cancer
cells use autophagy to survive?
We worked in the apoptosis field for many, many years
and we accidentally stumbled upon autophagy when we
were looking at cancer cells where the cell death path-
way of apoptosis was shut off. What we found was that
these cancer cells could survive prolonged starvation.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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off the cell death mechanism. When we looked at these
cells closely, we found out that they had activated the
autophagy pathway and were surviving by autophagy.
That was clear because if we deleted autophagy in these
tumour cells and then starved them, then they now died.
That revealed to us for the first time that autophagy was
a survival pathway that normal cells use, which cancer
cells could take advantage as well. We felt very strongly
that if there was a survival pathway used by cancer cells,
we need to inhibit it to promote the demise of those can-
cer cells. At that point, my lab transitioned from working
on mostly apoptosis to working on mostly autophagy.
Shortly thereafter we looked into tumours and discovered
that autophagy was often upregulated in hypoxic tumour
regions—those are regions deprived of oxygen—and when
we delete autophagy in those tumour cells, then you
end up with no tumour cells surviving hypoxia. So, that
suggested that even in vivo, autophagy was an important
survival mechanism for cancer cells.
Given that cancer cells can be reliant on autophagy, is
there a way that we can use this reliance to develop new
treatments for cancer?
That is the whole idea. But that is a very big job and a
very big commitment, and so we felt that what we
needed to do was to use the most powerful and physio-
logical tools at our disposal to validate that autophagy
was in fact a critical survival mechanism for certain can-
cers and try to figure out which cancers those are.
We embarked on large projects where we deleted an es-
sential autophagy gene in genetically engineered mouse
models for cancer. In these mouse models, cancers arise
through activation of a specific oncogene and/or deletion
of a known tumour suppressor gene, very much like what
would happen naturally in a human. The tumours evolve
from these events in a single cell, and with a functioning
normal immune system. When you inactivate autophagy
in k-ras- and b-raf-driven models of non-small-cell lung
cancer, there is a dramatic reduction in tumour growth.
That encouraged us that, yes, in the most physiological
settings we can model in the laboratory, at least in those
models for lung cancer, autophagy was providing an
important survival function for those cancers.
I think it is worthwhile now to consider targeting
some of the key components of the autophagy pathway
with small molecules to try to attempt to block autoph-
agy in patients. There are, however, clinical trials that
are currently active using hydroxychloroquine, which is
a lysosomotropic drug that interferes with the function
of lysosome. When cells eat themselves by autophagy,
ultimately all the cargo gets degraded in the lysosome.
Hydroxycholoroquine is a currently available drug for
malaria prophylaxis that can block the degradation ofthe cargo delivered to the lysosome by autophagy. Re-
cent papers have just been published that suggest that
there might be some activity of hydroxychloroquine in
various human clinical trials for cancer.
Given that autophagy is an essential process for normal
cells, is there a risk that blocking autophagy would have
some toxicity?
Absolutely an important question. Once we had evi-
dence that shutting off autophagy in a tumour impaired
the growth of those tumours, we then designed mouse
models to test exactly that. This involved making a
mouse where we can shut off autophagy by deleting an
essential autophagy gene at will throughout the mouse,
by providing a small drug—in this case tamoxifen—that
can control the deletion of an essential autophagy gene.
We engineered those mice so that they would also be
separately able to create lung cancer when we had the
mice inhale an adenovirus expressing Cre recombinase
to activate RAS and to delete p53 in the lung [1].
The bottom line is that we could shut autophagy off in
an adult mouse and then look to see how the normal
adult mouse responded—that was step number one.
Then, we would have an idea of what the toxicity would
be of an autophagy inhibitor. Then, in step two, we
could make a mouse with lung cancer and then delete
the essential autophagy gene throughout the mouse,
mimicking cancer therapy, and we could see if the
tumour died before the deleterious consequences to the
normal tissues of the mouse.
The results from those experiments are that when we
take an adult mouse and we delete an autophagy gene
throughout the whole mouse, the mouse is basically fine
for a while [1]. This was good news; our data showed
that normal tissues could, at least in the short term,
tolerate the absence of autophagy. Eventually, at between
2 and 3 months post-deletion, the mice showed damage
to important tissues like the liver, brain and muscle and
died [1]. So there is a window where loss of autophagy
has not too deleterious consequences to the mouse.
With that good news, we made mice with lung cancer
and then we shut autophagy off. We looked 5 weeks
after autophagy was ablated systemically in the mice and
the normal tissues at that point are mostly fine, but the
tumours were destroyed [1]. That was, I think, the
genetic experiment that establishes that, at least in lung
cancer, systemic ablation of autophagy may be thera-
peutically valuable.
Will autophagy inhibition work as a treatment for many
different cancers, or just to some?
I think it is entirely possible that not all tumours will be
sensitive to autophagy inhibition. Right now, we do not
really have a way to tell, although a number of people
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is a good place to start. We are making other mouse
models, for example prostate cancer and melanoma,
using activation of different oncogenes and deficiency in
different tumour suppressor genes, so that the mouse
models might direct us to one cancer over another, de-
pending on what the results are.
The pharmaceutical industry is working on autophagy
inhibitors, so it would be very nice to have those re-
agents to test in the laboratory to see how effective they
are. You have to remember that our genetic experiments
represent an extreme case; we have complete loss of an
essential autophagy gene and it is irreversible. So with a
small-molecule autophagy inhibitor, you are not likely to
get 100% inhibition that is irreversible. That is good and
that is bad. It may be that it will be bad if we cannot
inhibit autophagy efficiently enough, but on the other
hand, it might be good because you may not need to
inhibit autophagy completely for five consecutive weeks
for the deleterious effects to appear in tumours. If it is
possible to have 90% inhibition of the pathway for a
shorter period of time, and normal tissue can recover
faster than tumour tissue, it might be very valuable.
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